Aull & Monroe Investment Management Corp Buys 977 Shares of Becton Dickinson and Co (NYSE:BDX)

Aull & Monroe Investment Management Corp raised its position in Becton Dickinson and Co (NYSE:BDX) by 61.1% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 2,577 shares of the medical instruments supplier’s stock after buying an additional 977 shares during the period. Aull & Monroe Investment Management Corp’s holdings in Becton Dickinson and were worth $552,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently made changes to their positions in BDX. Exane Derivatives boosted its position in shares of Becton Dickinson and by 848.6% in the 4th quarter. Exane Derivatives now owns 702 shares of the medical instruments supplier’s stock worth $150,000 after purchasing an additional 628 shares during the last quarter. IFM Investors Pty Ltd boosted its position in shares of Becton Dickinson and by 16.2% in the 4th quarter. IFM Investors Pty Ltd now owns 7,376 shares of the medical instruments supplier’s stock worth $1,579,000 after purchasing an additional 1,028 shares during the last quarter. BB&T Corp boosted its position in shares of Becton Dickinson and by 8.2% in the 4th quarter. BB&T Corp now owns 5,555 shares of the medical instruments supplier’s stock worth $1,189,000 after purchasing an additional 419 shares during the last quarter. Cigna Investments Inc. New boosted its position in shares of Becton Dickinson and by 11.8% in the 4th quarter. Cigna Investments Inc. New now owns 9,741 shares of the medical instruments supplier’s stock worth $2,085,000 after purchasing an additional 1,025 shares during the last quarter. Finally, Welch & Forbes LLC boosted its position in shares of Becton Dickinson and by 2.2% in the 4th quarter. Welch & Forbes LLC now owns 78,065 shares of the medical instruments supplier’s stock worth $16,711,000 after purchasing an additional 1,676 shares during the last quarter. Hedge funds and other institutional investors own 75.56% of the company’s stock.

In other Becton Dickinson and news, Director Timothy M. Ring sold 269,661 shares of Becton Dickinson and stock in a transaction dated Thursday, February 8th. The stock was sold at an average price of $217.82, for a total value of $58,737,559.02. Following the sale, the director now owns 295,753 shares of the company’s stock, valued at approximately $64,420,918.46. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 1.00% of the company’s stock.

BDX has been the topic of several recent research reports. Zacks Investment Research upgraded Becton Dickinson and from a “hold” rating to a “buy” rating and set a $240.00 price target on the stock in a research report on Wednesday, January 3rd. Deutsche Bank set a $260.00 price objective on Becton Dickinson and and gave the stock a “buy” rating in a research note on Friday, December 29th. Argus raised their price objective on Becton Dickinson and to $235.00 and gave the stock a “buy” rating in a research note on Thursday, December 14th. They noted that the move was a valuation call. Stifel Nicolaus reaffirmed a “buy” rating and set a $245.00 price objective on shares of Becton Dickinson and in a research note on Friday, November 3rd. Finally, Bank of America reaffirmed a “buy” rating and set a $260.00 price objective on shares of Becton Dickinson and in a research note on Friday, January 19th. Four research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $237.27.

Shares of Becton Dickinson and Co (BDX) opened at $218.89 on Tuesday. Becton Dickinson and Co has a 12 month low of $175.66 and a 12 month high of $248.39. The stock has a market capitalization of $57,811.89, a PE ratio of 22.52, a price-to-earnings-growth ratio of 1.49 and a beta of 1.12. The company has a quick ratio of 0.93, a current ratio of 1.54 and a debt-to-equity ratio of 1.04.

Becton Dickinson and (NYSE:BDX) last released its quarterly earnings results on Tuesday, February 6th. The medical instruments supplier reported $2.48 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.41 by $0.07. Becton Dickinson and had a return on equity of 16.19% and a net margin of 2.71%. The firm had revenue of $3.08 billion for the quarter, compared to the consensus estimate of $3.05 billion. During the same quarter last year, the business posted $2.33 EPS. The company’s revenue for the quarter was up 5.4% on a year-over-year basis. equities research analysts forecast that Becton Dickinson and Co will post 10.95 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Friday, March 30th. Shareholders of record on Friday, March 9th will be paid a $0.75 dividend. This represents a $3.00 annualized dividend and a dividend yield of 1.37%. The ex-dividend date of this dividend is Thursday, March 8th. Becton Dickinson and’s dividend payout ratio is 229.01%.

WARNING: “Aull & Monroe Investment Management Corp Buys 977 Shares of Becton Dickinson and Co (NYSE:BDX)” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this report can be accessed at https://www.dispatchtribunal.com/2018/02/13/aull-monroe-investment-management-corp-buys-977-shares-of-becton-dickinson-and-co-bdx.html.

Becton Dickinson and Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply